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1a,25-Dihydroxyvitamin D3, the biologically active
form of vitamin D3, is a potent immunomodulatory
molecule; however, its clinical use as an immunosup-
pressant is limited due to its strong e¡ects on calcium
homeostasis and the risk of associated side-e¡ects. Here,
we present a representative of a novel class of vitamin D
analogs that exhibits potent immunosuppressive activ-
ity in a murine model of contact hypersensitivity when
applied systemically and is e⁄cacious also at nonhyper-
calcemic dosages. In vitro analysis revealed a binding af-
¢nity of ZK 191784 to the vitamin D receptor
comparable with 1,25-dihydroxyvitamin D3. This com-
pound inhibits lymphocyte proliferation and secretion
of tumor necrosis factor a and interleukin-12 in mono-
cytes in a concentration-dependent manner, but with
reduced potency and e⁄cacy than 1,25-dihydroxy-
vitamin D3. Treatment of human monocytes with this
analog signi¢cantly reduces expression of major histo-
compatibility complex class II, B7.1, and intercellular
adhesion molecule-1 equipotent to 1,25-dihydroxyvita-
min D3. Interestingly, the compound failed to induce
vitamin D-induced di¡erentiation of human promyelo-
cytic leukemia cell line HL-60 to monocytes and was
capable of antagonizing the action of 1,25-dihydroxyvi-
tamin D3. In vivo, as analyzed in mice the compound
potently inhibits the contact hypersensitivity when ap-
plied systemically. ZK 191784 has a clear therapeutic ad-
vantage over 1,25-dihydroxyvitamin D3 by inducing
immunosuppressive e¡ects also at concentrations that
do not cause hypercalcemia. ZK 191784 is the ¢rst repre-
sentative of a novel class of vitamin D analogs that
might have therapeutic potential in Tcell-mediated im-
mune disorders. Key words: autoimmunity/in£ammation/
skin/T lymphocytes. J Invest Dermatol 119:1434 ^1442, 2002
1,25-Dihydroxyvitamin D3 (calcitriol), the activated form of
vitamin D3 binds to a nuclear receptor protein named vitamin
D receptor (VDR). In addition to its prominent role in calcium
homeostasis and bone metabolism (Jones et al, 1998), it has been
widely accepted that calcitriol has also immunomodulating prop-
erties, including regulation of cell di¡erentiation and e¡ector
functions of di¡erent immune cells (Hewison, 1992; Casteels
et al, 1995; Lemire, 1995). Recent in vitro ¢ndings indicate that cal-
citriol inhibits di¡erentiation and maturation of dendritic cells,
leading to the downregulated expression of surface molecules re-
quired for optimal T cell activation, such as major histocompat-
ibility complex (MHC) class II and costimulatory molecules
(Penna and Adorini, 2000; Piemonti et al, 2000; Gri⁄n et al,
2001). Similarly, on monocytes, MHC class II as well as costimu-
latory molecule expression are prominently downregulated by
calcitriol (Rigby andWaugh, 1992; Tokuda et al, 1992).
Induction of T cell responses requires T cell receptor activation
(via speci¢c antigenic determinants presented by MHC mole-
cules) and costimulatory interaction between antigen-presenting
cells (APC) and T cells. If T cells receive an incomplete stimula-
tion, activity of T cells is reduced or T cells can become anergic
(Schwartz, 1997). For calcitriol direct e¡ects on activated Tcells by
inhibition of T cell receptor- or lectin-mediated proliferation and
cytokine release have been described (Provvedini et al, 1983; Rig-
by et al, 1984, 1987). Overall, the current understanding of inhibi-
tion of T cell activity by calcitriol is that to a minor extent the T
cell but more the APC represent the major target for immuno-
modulatory activity of calcitriol (Penna and Adorini, 2000). Thus,
the calcitriol-induced modulation of surface molecule expression
or release of de¢ned cytokines byAPC then in second line pro-
vide e¡ective inhibition of T cell activity. Several lines of evi-
dence indicate that calcitriol interferes preferentially with T
helper (Th) 1 responses by inhibition of interferon g and interleu-
kin (IL)-12 production and augmenting Th2 cell development
(IL-4, IL-5, and IL-10 production) (Lemire et al, 1995; Mattner
et al, 2000).
Immunosuppressive and therapeutic activity upon systemic ad-
ministration has been demonstrated for calcitriol in models for
human diseases, such as in experimental encephalomyelitis, col-
lagen-induced arthritis, autoimmune thyroiditis, allogenic trans-
plantation, diabetes, and in£ammatory bowel disease (Jordan et al,
1988a,b; Fournier et al, 1990; Lemire and Archer, 1991; Lemire et al,
1992; Cantorna et al, 1996, 1998, 2000; Casteels et al, 1998; Mattner
et al, 2000). In these studies, systemic therapy with calci-
triol resulted in signi¢cant inhibition of disease symptoms, or
prevention of disease onset, or in the case of transplantation, pro-
longation of graft survival. Beside its attractive immunosupp-
ressive characteristics, however, calcitriol has clear dose-limiting
hypercalcemic e¡ects. Thus, the systemic clinical use of calcitriol
(e.g., in renal osteodystrophy, psoriasis, rheumatoid arthritis) is
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limited due to its strong e¡ects on calcium homeostasis and the
risk of associated side-e¡ects, such as renal and heart failure and
reduction in bone mineral density (Slatopolsky et al, 1984; Perez
et al, 1996; Andjelkovic et al, 1999). There has, therefore, been a
great e¡ort in identifying new vitamin D analogs that share with
calcitriol the immunosuppressive properties but lack the calcemic
activity. Consequently, such dissociated compounds would have a
signi¢cantly more favorable therapeutic pro¢le than calcitriol.
Over the past years, several systemically active calcitriol analogs
have been identi¢ed that share with calcitriol the immunomodu-
latory capacity but are characterized by a reduced hypercalcemic
risk (reviewed by Mathieu and Adorini, 2002). So far, no calci-
triol derivative showing dissociation between immunosuppres-
sion and hypercalcemia after systemic application has been
approved for application in humans.
Here we describe a newly identi¢ed calcitriol derivative with
structural modi¢cations concerning the chemical side chain with
immunosuppressive activity and less hypercalcemic activity. Initi-
ally, this analog has been tested for its capacity to inhibit T cell
proliferation in the mixed leukocyte reaction (MLR). We then
examined immunomodulatory e¡ects on monocytes, such as re-
lease of tumor necrosis factor (TNF)-a and IL-12 as well as ex-
pression of MHC and costimulatory molecules. Finally, we
investigated whether this derivative is capable of exerting immu-
nosuppressive activity in a contact hypersensitivity (CHS) model
in mice when applied systemically at concentrations that do not
cause hypercalcemic e¡ects. ZK 191784 is the ¢rst representative of
a novel class of vitamin D analogs that might have a potential
therapeutic value for the treatment of T cell-mediated immune
disorders.
MATERIALS AND METHODS
Mice and cells Female 8^12 wk old NMRI mice (26^28 g in body
weight) were purchased from Sch˛nwalde breeding facilities
(Sch˛nwalde, Germany). Animals were housed in the animal facility at
Schering AG (Berlin, Germany) and received a chow with a standard
calcium content (1%).
Vitamin D3 Calcitriol (purchased from Solvay-Duphar, Brussels,
Belgium) and the analog (5Z,7E,22E)-(1S,3R,24R)-25-(5-Butyloxazole-
2-yl)-26,27-cyclo-9,10-secocholesta-5,7,10 (19),22-tetraene-1,3,24-triol (ZK
191784, molecular weight 535.767 g per mol, synthesized as previously
described; Steinmeyer et al, 1997), were dissolved in ethanol at a
concentration of 110^2 mol per liter and kept at 201C. The structures
of calcitriol and ZK 191784 are illustrated in Fig 1. 1a,25-Dihydroxy-
[26,27-methyl-3H] cholecalciferol (speci¢c activity 180 Ci per mmol) was
obtained from Amersham Pharmacia Biotech (Freiburg, Germany) and
dissolved in ethanol and kept at ^201C.
VDR binding assay Using radioactively labeled calcitriol the a⁄nity of
ZK 191784 to the VDRwas determined in a competition ligand-binding
assay. A nuclear fraction was obtained from the intestinal mucosa of a
juvenile pig as previously described (Horst et al, 1983). This VDR
preparation (0.8 mg protein per ml) was incubated with [26,27-
methyl-3H] 1a,25-dihydroxycholecalciferol (5.41010 mol per liter, 925
Bq per tube) in the presence of increasing concentrations (1012^106 mol
per liter) of unlabeled calcitriol or ZK 191784 for 120 min at 41C.
Separation of VDR-bound ligand from unbound material was achieved
by absorption of the free ligand to dextran-coated charcoal, followed by
centrifugation. The supernatant (400 ml) was mixed with 3.5 ml
scintillation cocktail (Pico£uor 15, Packard Biosciences, the Netherlands)
and the radioactivity quanti¢ed by b-plate scintigraphy (1450 Microbeta
Trilux, Wallac, Finland). The binding a⁄nity of ZK 191784 to the VDR
was expressed relative to calcitriol.
Assay on di¡erentiation of HL-60 cells to macrophages It has been
reported that the promyelocytic leukemia cell line HL-60 di¡erentiates in
the presence of vitamin D derivatives to macrophage-like CD14 expressing
cells (Mangelsdorf et al, 1984). For induction of di¡erentiation, HL-60 cells
(obtained from American Type Culture Collection, Manassas, VA) were
cultured at a density of 2.5105 cells per ml in the presence of di¡erent
concentrations of calcitriol or ZK 191784 and incubated for 4 d in RPMI
1640 medium supplemented with fetal bovine serum (10% v/v) at 371C
and 5% CO2. Antagonistic activity of ZK 191784 was investigated by
cotreatment of HL-60 cells with di¡erent concentrations of calcitriol and
ZK 191784 as indicated in Fig 2. The cell surface antigen CD14, which is
speci¢c for mature monocytes/macrophages, was detected in di¡erentiated
HL-60 cells with £uorescein isothiocyanate (FITC)-conjugated CD14
monoclonal antibody (MoAb) from Becton Dickinson (San Jose, CA) and
quanti¢ed by £ow cytometry. E¡ective concentration values represent the
concentration of compound that induced 50% (EC50) of the cells to be
CD14 positive.
Peripheral blood mononuclear cells (PBMC) proliferation
assays Human PBMC obtained from healthy donors were isolated by
centrifugation of heparinized blood on Histopaque-1077 (Sigma, St
Louis, MO) and cultured in RPMI 1640 medium supplemented with fetal
bovine serum (10% v/v). For stimulation with phytohemagglutinin (PHA),
PBMC 2.5105 cells per ml were seeded in the presence of PHA (5 mg per
ml) (Sigma) in 96 well £at-bottom microtest plates (Costar, Cambridge,
MA). For MLR, responder PBMC (5104 cells per well) were seeded
together with mitomycin C-treated stimulator PBMC (1105 cells per
well) from an unrelated donor in 96 well round-bottom microtest plates
(Costar). For mitomycin C treatment cells were incubated with 50 mg
mitomycin C per ml for 30 min at 371C followed by repeated washings
with phosphate-bu¡ered saline. After triplicate culture set up vitamin D
compounds were added and plates were cultivated at 371C. On day 4
(PHA stimulation) or day 5 (MLR) PBMC were pulse labeled with
[methyl-3H]thymidine (0.2 mCi per well) for 6 h and harvested on glass
¢lters. [3H]thymidine incorporation of triplicate culture set-ups was
measured by liquid scintillation counts quanti¢ed by b-plate scintigraphy
(1450 Microbeta Trilux, PerkinElmer Life Sciences, Turku, Finland).
Di¡erent stimulator cell numbers (for MLR) or concentration of PHA
have been tested. Optimal proliferative responses of lymphocytes resulted
with the stimulatory conditions described above.
Flow cytometry PBMC were isolated as described above and cultured
(1106 cells per ml) in RPMI 1640 medium supplemented with fetal
bovine serum (10% v/v) for 48 h in 12-well plates (Costar) in the presence
or absence of di¡erent concentrations of ZK 191784 or calcitriol as indicated
in Fig 2 and Fig 4. Afterwards PBMC were stained with the following
MoAb: FITC-conjugated CD14 MoAb from Becton Dickinson;
phycoerythrin-conjugated CD14 MoAb, Cy-chrome-conjugated CD54
MoAb [anti-intercellular adhesion molecule-1 (anti-ICAM-1)], FITC-
conjugated CD80 MoAb (anti-B7.1), FITC-conjugated HLA-A,B,C (anti-
MHC class I), and phycoerythrin-conjugated HLA-DR (anti-MHC class
II) from Pharmingen (Lajolla, CA). After extensive washing, monocytes
gated according to scatter characteristics and CD14 positivity, were
analyzed on a FACScan £ow cytometer (Becton Dickinson) for cell
surface expression levels of CD14, HLA-DR, HLA-A,B,C, B7.1, and
ICAM-1. Results are expressed as the relative expression¼mean
£uorescence of substance-treated CD14þ monocytes/mean £uorescence of
untreated CD14þ monocytes.
Cytokine release assay Human PBMC (isolated as described above)
were cultured in RPMI 1640 medium supplemented with fetal bovine
serum (10% v/v). PBMC (1106 cells per ml) were seeded in 300 ml
medium in 96-well £at bottom microtiter plates (Costar) and stimulated
with 100 ng lipopolysaccharide (LPS) per ml from Escherichia coli, Type
L2880 (Sigma). After triplicate culture was set up, compounds were added
and plates were cultivated at 371C. After 16 h (for TNF-a and IL-12) or 20
h (for IL-10) of culture, supernatants were collected and stored at ^801C.
Cytokine levels were quanti¢ed in duplicate by enzyme-linked
Figure1. Chemical structure of the vitamin D analog ZK 191784.
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immunosorbent assay using commercial kits from BioSource International
Inc. (Camarillo, CA; TNF-a, IL-10) and R&D (Minneapolis, MN; IL-12
p40 and p70).
Mouse CHS For sensitization female NMRI mice were topically treated
on day 0 and day 1 with 25 ml of 0.5% (w/v) 2,4-dinitro£uorobenzene
(DNFB) (Sigma) in acetone/olive oil 4 : 1 (v/v) on the shaved abdomen.
After 5 d, groups of 10 mice were challenged by the topical application of
20 ml of 0.3% (w/v) DNFB in acetone/olive oil 4 : 1 (v/v) on both sides of
one ear. Compounds were applied subcutaneously into the neck in a
volume of 0.1 ml per 20 g body weight in 0.9% NaCl solution containing
0.085% Myrj 53 (ICI, Ablestik Laboratories, Cambridge, UK) and 5%
ethanol. Animals were treated once daily for 5 d around the sensitization
phase (days ^2, ^1, 0, 1, and 2). On day 6 (24 h after challenging animals)
the thickness of the in£amed ear was determined and elastase activity, a
parameter for neutrophil in¢ltration, was measured. Groups of DNFB-
untreated (No DNFB) and DNFB-sensitized and -challenged mice
(DNFB/DNFB) served as negative and positive controls, respectively. To
monitor possible side-e¡ects, the body weight of the animals before and
after treatment with compounds, calcium levels in urine and spleen
weights were determined on days 2 and 6, respectively.
Detection of elastase activity in ear homogenates Elastase activity
represents a speci¢c indicator for neutrophil in¢ltration. For
determination of calcitriol-mediated e¡ects on neutrophil in¢ltration in
the CHS reaction, ears were homogenized in 0.5% HTAB-bu¡er (hexa-
decyltrimethylammonium bromide) and 10 mM 4-morpholinepropane-
sulfonic acid (Sigma). Elastase activity in ear homogenates was quanti¢ed
photometrically by enzymatic cleavage of 7-Amino-4 -methyl-coumarin
(AMC) from the substrate MeO-Succ-Ala-Ala-Pro-Val-AMC (Bachem,
Heidelburg, Germany). Homogenate samples were diluted 1 : 10 in
Cetrimid bu¡er (0.3% Cetrimid, 0.1 M Tris, 1 M NaCl; pH 8.5). Samples
(20 ml) were pipetted in 96-well black solid opaque plates (Costar) and
the reaction started by addition of 20 ml of the AMC substrate (3 mM in
Cetrimid bu¡er) at 371C. The reaction was stopped after 1 h with ice-cold
100 mM Na2CO3 and samples analyzed by a Spectra Max Gemine
(Molecular Devices, Ltd, Wokingham, U.K.) at 380 nm. Measurements
were compared against a standard curve with AMC standard 7-amino-4-
methylcoumarin (5 mM in ethanol).
Detection of calcium levels For measurement of total calcium in urine
and serum from mice collected on day 5 of compound treatment (24 h
after the fourth treatment), samples were diluted 1 : 2 with H2O and
analyzed by the £ame photometer AFM 5051 (Eppendorf, GmpH,
Hamburg, Germany) against a standard curve prepared from a urine
standard solution containing 5 mM calcium (Eppendorf).
Statistics The statistical signi¢cance of di¡erences in the means for each
experimental group vs the positive control (DNFB/DNFB) was calculated
with the Student’s t test for independent samples. po 0.05 was considered
as signi¢cant.
RESULTS
VDR binding and antagonism of calcitriol-induced
di¡erentiation of HL-60 cells by ZK 191784 Binding of
calcitriol or analogs to the nuclear VDR is essential for
mediating their biologic activities, including immuno-
modulatory e¡ects. Therefore, the initial objective of the in vitro
characterization of ZK 191784 was to demonstrate that the
compound is capable of binding speci¢cally to the VDR.
Results indicate a signi¢cant displacement of radioactively
labeled calcitriol by ZK 191784 from the VDR, thus ZK 191784
competed with [3H]calcitriol for binding to the VDR. The
binding a⁄nity of ZK 191784 relative to calcitriol was
determined to be 33%. These studies show that the side chain
modi¢cation in the chemical structure of ZK 191784 interferes
only slightly with VDR binding as ZK 191784 binds with an
a⁄nity close to calcitriol to the VDR.
In order to study biologic e¡ects mediated through VDR
ligation the HL-60 di¡erentiation assay was employed. The
human promyelocytic leukemia cell line HL-60 constitutively
expresses the VDR. These cells can be induced to di¡erentiate
towards monocytes/macrophages by VDR ligands (Mangelsdorf
et al, 1984). The degree of di¡erentiation induced by calcitriol was
monitored by measuring the percentage of cells expressing the
monocyte/macrophage cell surface marker CD14. Calcitriol
induced CD14 expression on HL-60 cells in a concentration-
dependent manner with a concentration to induce 50% of the
maximum e¡ect (EC50) of 6.910
^9 mol per liter and an
e⁄cacy of 4 80% that was achieved with 10^7 mol per liter
calcitriol (Fig 2). In contrast, ZK 191784 exerted only weak
agonistic e¡ects inducing CD14 expression on HL-60 cells with
an e⁄cacy of 20% at 310^6 mol per liter ZK 191784. By
concomitant addition of ZK 191784 (10^6 mol per liter) to
calcitriol the EC50 for calcitriol to induce di¡erentiation was
signi¢cantly enhanced. These results demonstrate that ZK 191784
behaves as an calcitriol antagonist with regard to induction of
di¡erentiation of HL-60 cells.
Inhibition of lymphocyte proliferation by ZK
191784 Immunosuppression a¡ecting lymphocyte activity in vivo
is a major task for e¡ective treatment of T cell-mediated diseases.
It is known that proliferation of lymphocytes and lymphokine
release in the presence or absence of APC can be inhibited
by VDR agonists in vitro, potentially re£ecting their immuno-
suppressive action in vivo (Lemire and Archer, 1991; Mattner et al,
2000; Boonstra et al, 2001). Therefore, ZK 191784 has been tested
for its capability to inhibit lymphocyte activity in comparison
with calcitriol. The compound was tested in the PHA-induced
lymphocyte proliferation assay and in the human MLR. In
contrast to unspeci¢c stimulation of lymphocytes via lectins
(e.g., PHA), stimulation of lymphocytes in the MLR depends
on the T cell receptor triggering by allogenic antigenic epitopes.
Proliferation of PBMC induced by PHA was inhibited by ZK
191784 in a concentration-dependent manner. As depicted in Fig
3(A), calcitriol inhibited [3H]thymidine incorporation with an
e⁄cacy of E60% at 110^7 mol per liter, whereas ZK 191784
Figure 2. ZK 191784 antagonizes the calcitriol-induced di¡erentiation of
HL-60 cells. ZK 191784 was added to cultured HL-60 cells in ethanol ve-
hicle in two doses as indicated in the graph to increasing concentrations of
calcitriol. After 5 d, cells were harvested and CD14 expression analyzed by
a £uorescence-activated cell sorter. EC50 values represent the concentration
of compound that induced 50% of the cells to be CD14+.
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reached similar e⁄cacy at concentrations 4 10^6 mol per liter.
The e¡ective concentration for half maximal inhibition (IC50)
was 7.97109 mol per liter for calcitriol and 4.2710^8 mol
per liter for ZK 191784. Thus, ZK 191784 exerts inhibitory
activity on lectin-stimulated proliferation of lymphocytes but is
less potent than calcitriol; however, the e⁄cacy of ZK 191784 in
PHA-stimulated PBMC is within the range of the e⁄cacy of
calcitriol.
Similarly, proliferation of PBMC was inhibited by ZK 191784
in a concentration-dependent fashion in the MLR (Fig 3B). The
IC50 values were 1.510
^8 mol per liter for calcitriol and 4.210^8
mol per liter for ZK 191784, whereas the e⁄cacy of ZK 191784
reached only 60% of the calcitriol reference. As observed in a
modi¢ed experimental MLR set-up with selected concentrations
of ZK 191784 and calcitriol, the inhibitory e¡ects of compounds
on lymphocytes seem to APC dependent. Here, stimulator cells
have been preincubated with compounds, followed by washing
steps.When applied to the MLR, these stimulator cells induced
signi¢cantly reduced proliferative response of allogenic
responder cells compared with untreated stimulator cells (results
not shown). Thus, ZK 191784 inhibits human PBMC
proliferation in an APC-dependent fashion with an e⁄cacy and
potency slightly inferior to calcitriol.
Down-modulation of HLA-DR, ICAM-1, and B7.1 cell
surface expression on monocytes by ZK 191784 In the
following ZK 191784 was evaluated for its regulatory e¡ects on
expression of B7.1, ICAM-1, and MHC class II (HLA-DR)
surface molecules on human monocytes as it is well known that
speci¢c intervention with expression of these molecules a¡ects T
cell activity. Treatment of PBMC for 48 h with ZK 191784 or
calcitriol resulted in a concentration-dependent inhibition of
monocytic surface expression of HLA-DR, B7.1, and ICAM-1
(Fig 4). Calcitriol results in maximum downregulation of MHC
class II at 110^8 mol per liter by 65% with an IC50 value
(concentration to induce 50% inhibition) of 9.610^10 mol per
liter. The maximum inhibitory e¡ect was for ZK 191784 (50%
inhibition) at 110^8 mol per liter with an IC50 of 1.910
9
mol per liter. ZK 191784 also inhibited B7.1 expression by 40%
at concentrations Z110^8 mol per liter (IC50¼3.710
^10 mol
per liter). The e¡ects induced by calcitriol were in the similar
range as for ZK 191784 (inhibition of B7.1 by 50%
at concentrations Z110^8 mol per liter with an IC50 of
9.210^10 mol per liter). A similar pattern has been observed
with modulation of adhesion molecule ICAM-1 expression,
which is signi¢cantly reduced by ZK 191784 (maximum
inhibition of 40%, IC50¼ 5.410
^10 mol per liter) and by
calcitriol (maximum inhibition of 50%, IC50¼ 4.810
^10 mol
per liter). Thus, with regard to B7.1 and ICAM-1
downregulation, ZK 191784 is slightly less e⁄cacious and
equipotent than calcitriol. Similarly, ZK 191784 is somewhat less
e¡ective in downregulation of HLA-DRon monocytes and has a
lower potency. In contrast, expression levels for HLA-A,B,C
remained in the range of untreated monocytes a phenomenon
that has been described also for calcitriol (Tokuda et al, 1992)
(results not shown). Interestingly, exposure of human monocytes
to calcitriol and ZK 191784 leads to an increase of CD14
expression levels. As monocyte to macrophage maturation also
correlates with an increase in CD14 expression, these ¢ndings
suggest that beside interference with speci¢c immune responses,
ZK 191784 and calcitriol also promote di¡erentiation of
monocytes to macrophages, which is a central issue in the
unspeci¢c immune response.
On the basis of these observations we conclude that the ability
of calcitriol derivatives to decrease MHC class II, B7.1, and
ICAM-1 expression levels on APC has an impact on APC-
dependent T cell activation and might be in particular relevant
for immunosuppressive properties.
Inhibition of LPS-induced cytokine secretion of human
monocytes by ZK 191784 Beside e¡ects on MHC class II and
costimulatory molecule expression, calcitriol has been shown to
inhibit IL-12 production by human monocytic cells (Mattner
et al, 2000). To determine whether this activity was shared also
by ZK 191784, this compound was tested for the ability to
inhibit IL-12 production by PBMC stimulated with LPS. As
depicted in Fig 5(A), LPS stimulation of human PBMC resulted
in a signi¢cant release of IL-12 p40. IL-12 p40 production was
inhibited by ZK 191784 and calcitriol in a concentration-
dependent fashion with similar potencies (IC50 between 3 and
510^9 mol per liter). Calcitriol showed highest inhibition of
IL-12 p40 (by E65%) apparent at concentrations 41107
mol per liter. In comparison, treatment with ZK 191784 resulted
only in a maximum inhibition (by 30%) at concentrations
4110^8 mol per liter. In order to address the e¡ect of
calcitriol derivatives on IL-12 p70 secretion in human
monocytes an additional experiment has been performed (using
high-sensitivity Quantikine enzyme-linked immunosorbent
Figure 3. Inhibition of human PBMC proliferation in the MLR and cultures stimulated with PHA by ZK 191784 and calcitriol. Human PBMC were
stimulated with PHA (A) or in the MLR (B) with mitomycin C-treated stimulator cells from an unrelated donor and cultured in the presence of increasing
doses of calcitriol or ZK 191784. On day 4 (PHA stimulation) or day 5 (MLR) cultures were pulse-labeled with [methyl-3H]thymidine for 6 h and harvested
on glass ¢lters. [3H]thymidine incorporation of triplicate culture set-ups was measured by liquid scintillation counts. Results are presented as mean7 SD of
triplicate cultures. Experiments have been repeated twice with similar results.
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assay; R&D) and these new data further support our previous
¢nding regarding IL-12. LPS stimulation (same conditions as for
IL-12 p40 analysis) of human PBMC resulted in a signi¢cant
release of IL-12 p70 (16 pg per ml). ZK 191784 inhibits IL-12
p70 release by a maximum of 36% at concentrations Z10^8 mol
per liter. In comparison, calcitriol inhibits IL-12 p70 release by a
maximum of 54% at concentrations Z10^8 mol per liter. These
data indicate that ZK 191784 is capable of interfering with
secretion of both forms of IL-12, p40, and p70, although to a
less magnitude than calcitriol.
Similarly, TNF-a levels secreted by LPS-stimulated human
PBMC were a¡ected by ZK 191784 (Fig 5B). Stimulation of
cultures with LPS resulted in 2200 pg TNF-a per ml serving
as the positive control. Calcitriol suppressed TNF-a release
with highest potency (IC50¼ 9.110
^10 mol per liter) and
a maximum inhibition of TNF-a release by 55% at concen-
trations Z10^7 mol per liter. In contrast, the concentrations for
half maximal inhibition for ZK 191784 was 2.210^9 mol per
liter. ZK 191784 showed inhibition of TNF-a release by 40% at
concentrations4110^7 mol per liter.
Taken together these ¢ndings show that ZK 191784 in
comparison with calcitriol is less e¡ective with regard to
inhibition of IL-12 (p40 and p70) and TNF-a production in
monocytes. As only marginal inhibition was observed for IL-10
secretion capacity these e¡ects can be accepted as partially
selective for proin£ammatory cytokines (Fig 5C). These data
implicate that ZK 191784 can inhibit IL-12 release by monocytes
and therefore is capable of interfering with the regulation of Th1
development, which has been also described for calcitriol (Lemire
et al, 1995; Mattner et al, 2000). Moreover, ZK 191784 shows
inhibition of TNF-a production of human monocytes
representing a major proin£ammatory cytokine. Potent
inhibition of IL-12 and TNF-a could be bene¢cial in vivo at sites
of in£ammation, where these cytokines are found to be
extremely elevated.
ZK 191784 impairs the murine CHS In order to analyze
whether the in vitro characteristics of ZK 191784 correspond with
inhibition of a T cell-mediated immune response in vivo, ZK
191784 has been tested in a murine model for CHS. Indeed,
treatment of mice with ZK 191784 resulted in the induction of
immunosuppressive activity. Two representative experiments are
depicted in Fig 6 that demonstrate concentration-dependent
inhibition of the CHS by treatment of mice with ZK 191784
Figure 4. Inhibition of HLA-DR, B7.1, and ICAM-1 surface marker expression on human monocytes by ZK 191784 and calcitriol. Human PBMC were
cultured in the presence or absence of increasing concentrations of ZK 191784 or calcitriol as indicated in the graph. After 48 h, PBMC were stained with
MoAb for CD14-, HLA-DR-, CD80 (B7.1), and CD54 (ICAM-1) expression and analyzed by a £uorescence-activated cell sorter. Results are expressed as the
relative expression¼mean £uorescence of substance-treated CD14+ monocytes/mean £uorescence of untreated CD14+ monocytes. The mean £uorescence
expression of markers on untreated monocytes were: CD14¼ 592; HLA-DR¼ 2990; ICAM-1¼2626; and B7.1¼46. These data are representative of three
separate experiments.
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around the sensitization phase. As demonstrated in Fig 6(A),
treatment with 0.3 mg ZK 191784 per kg per day caused
inhibition of edema formation by 42% compared with positive
control (DNFB-DNFB). In this particular experiment
statistically signi¢cant inhibition of edema formation has been
calculated for doses 10, 60, and 300 mg per kg per day resulting
in inhibition of 58%, 60%, and 68%, respectively. Also,
neutrophil in¢ltration was signi¢cantly inhibited by all doses of
ZK 191784 as analyzed by elastase activity in ear homogenates
(Fig 6B). Similarly, treatment with calcitriol (0.1 mg per kg per
day) caused signi¢cant inhibition of edema formation and
neutrophil in¢ltration. The therapeutic e⁄cacy for calcitriol,
however, was associated with a signi¢cant increase in calcium
excretion as determined in the urine of animals after 4 d
treatment with calcitriol. In contrast, a signi¢cant increase
(po0.05) in urine calcium occurred at 300 mg ZK 191784 per kg
per day (Fig 6C). Serium calcium levels were signi¢cantly
elevated (po0.05) for 0.1 mg per kg per day of Calcitriol (2.92
mmol per liter) and 300 mg per kg per day of ZK 191784 (2.98
mmol per liter) in comparison to untreated control (2.62mmol
per liters). Serium calcium levels were in the normal range for
other doses of ZK 191784.
Importantly, by decreasing the concentrations of calcitriol the
therapeutic e⁄cacy on edema formation in mice diminished
(statistical signi¢cance only at 0.1 mg per kg per day with 48%
inhibition of the CHS), whereas the urine calcium levels
remained signi¢cantly elevated also at doses (0.06 and 0.03 mg
per kg per day) with only weak therapeutic e⁄cacy (Fig 6D,E).
Signi¢cant serum calcium changes (po0.05) occurred only for
0.1 mg calcitriol per kg per day (2.96 vs 2.57 mmol per liter in the
control group). Serum calcium levels in the normal range for
other doses of were ZK 191784.
Thus, no dissociation between immunosuppressive e¡ects and
hypercalciuria exists for calcitriol. Again, ZK 191784 exerted
therapeutic e⁄cacy on edema formation at doses that do not
cause a signi¢cant increase in urine calcium levels. Therefore,
ZK 191784 in contrast to calcitriol has a reasonable therapeutic
window (dissociation factor of approximately 20) in the murine
CHS model. No changes in body weights and spleen weights
were observed for nonhypercalciuric doses. In mice, a
statistically signi¢cant increase of urine calcium levels occurs for
ZK 191784 at dosesZ300 mg per kg per day.
No signi¢cant inhibition of edema was observed when ZK
191784 or calcitriol have been administered around the phase of
hapten challenge (in contrast to glucocorticoids, e.g., dexametha-
sone, results not shown) suggesting that calcitriol derivatives
exert immunosuppressive activity by targeting primarily APC
causing inhibition of antigen presentation for the initial hapten
priming of naive T cells to become e¡ector T cells in vivo.
DISCUSSION
Immunomodulatory properties of calcitriol make it a promising
treatment for di¡erent diseases; however, its use in the clinic has
been limited because it causes hypercalcemia at pharmacologi-
cally e¡ective doses. Therefore, the major aim of research activ-
ities in this ¢eld is to identify new vitamin D analogs that share
with calcitriol the immunosuppressive properties but lack the cal-
cemic activity. Extensive compound ¢nding programs led to the
identi¢cation of a few vitamin D analogs that combine therapeu-
tic e⁄cacy with an improved side-e¡ect pro¢le (Nagpal et al,
2001; Mathieu and Adorini, 2002); however, a calcitriol derivative
showing dissociation between immunosuppression and hypercal-
cemia after systemic application has not yet been approved for
application in humans. Still the molecular basis of dissociation is
incompletely understood and is often a matter of speculation. It
has been hypothesized that de¢ned modi¢cations concerning the
vitamin D side chain and weak binding a⁄nity to the serum
vitamin D binding protein often correlate with less calcemic
potential in vivo (Bouillon et al, 1995; Nagpal et al, 2001). As out-
lined in this study, ZK 191784 combines these features with a un-
ique biologic pro¢le.
ZK 191784 is chemically characterized by a 22,23-double bond,
24R-hydroxy group, a 25-cyclopropyl ring, and a 5-butyloxazole
unit (Fig 1). ZK 191784 binds with a slightly lower a⁄nity to
VDR compared with calcitriol, which indicates that modi¢ca-
tions regarding the side chain have no major in£uence on bind-
ing behavior to the VDR. Binding a⁄nity of ZK 191784
to the vitamin D binding protein was fully absent, however,
whereas considerable binding a⁄nity of calcitriol to the vitamin
D binding protein has been demonstrated (a⁄nity of calcitriol
approximately 15-fold less than the standard ligand 25-hydroxy-
cholecalciferol, results not shown). On the basis of these data
it can be proposed that transport conditions of ZK 191784 in
serum vary to some extent from calcitriol and may have conse-
quences for di¡erent metabolic stability and distribution pattern
in vivo.
The promyelocytic human cell line HL-60 expresses theVDR
and can be di¡erentiated to macrophage-like cells by vitamin D
derivatives (Mangelsdorf et al, 1984). These cells are often used in
vitamin D research (Boehm et al, 1999) and have been also applied
in our approach to identify new calcitriol analogs for an initial
characterization of compounds for their biologic ability mediated
through the VDR. Interestingly, ZK 191784 antagonized calci-
triol-induced di¡erentiation of HL-60 representing an e¡ect that
has been described earlier for a di¡erent class of vitamin D deri-
vatives (Miura et al, 1999). To us these results provided the ¢rst
evidence that ZK 191784 has a biologic pro¢le distinct from
calcitriol.
Figure 5. Inhibition of LPS-induced secretion of IL-12 (A),TNF-a (B) and IL-10 (C) of human PBMC by ZK 191784 and calcitriol. Human PBMC were
cultured for 16 h and primed with 100 ng LPS per ml from E. coli in the presence of increasing doses of calcitriol or ZK 191784. Afterwards, supernatants
were collected and cytokine levels analyzed by enzyme-linked immunosorbent assay. Results are presented as mean 7 SD of triplicate cultures. This ex-
periment has been repeated twice with similar results.
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Activation of T cells requires two signals from APC, ¢rst via
the speci¢c antigen/MHC complexes, and secondly via costimu-
latory molecules, such as B7 (Schwartz, 1997). For initial interac-
tion of T cells with APC a su⁄cient expression of cell adhesion
molecules is necessary, such as ICAM-1. Vitamin D is known to
regulate expression of MHC class II, costimulatory, and cell adhe-
sion molecules (Rigby andWaugh, 1992;Tokuda et al, 1992; Clav-
reul et al, 1998). Other studies point to immunomodulatory e¡ects
induced by vitamin D via modulation of cytokine expression
(Piemonti et al, 2000; Mattner et al, 2000). Among the cytokines
strongly in£uenced by calcitriol, and TNF-a and IL-12 represent
prominent players in acute in£ammation and in regulation of
Figure 6. Inhibition of the DNFB-induced CHS in mice by treatment with ZK 191784 or calcitriol. Groups of 10 NMRI mice were topically sensitized
with DNFB (or vehicle, as controls) at the shaved abdomen. Five days later, all mice were challenged with DNFB on both sides of one ear. Mice were treated
with compounds once daily for 5 d around the sensitization phase. On day 6 (24 h after challenging animals) ear thickness and elastase levels as a parameter
for neutrophil in¢ltration were determined in homogenized ears. Urine samples were collected 24 h after the fourth treatment and analyzed for calcium
levels by £ame photometry. Data of two independently performed experiments are displayed: experiment 1 (A^C), and experiment 2 (D,E). Positive controls
consisted of DNFB-sensitized and DNFB-challenged mice. Negative controls consisted of unsensitized mice that were ear challenged only. Data are ex-
pressed as the mean7SD. Experiments were repeated at least three times with similar results. Statistical signi¢cance: npo 0.05, nnpo 0.001.
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lymphocyte responses. As shown in this study, ZK 191784 inhibits
expression of HLA-DR, B7.1, and ICAM-1 on monocytes as well
as IL-12 and TNF-a secretion of human PBMC, therefore has si-
milar to calcitriol profound immunomodulatory activity. Data
from lymphocyte proliferation assays provide experimental proof
that ZK 197184 has an impact also on the activity of lymphocytes.
Here, ZK 191784 and calcitriol inhibited the lectin-mediated sti-
mulation as well as stimulation of lymphocytes in the MLR,
which depends on T cell receptor triggering by allogenic anti-
genic epitopes. In comparison with calcitriol, the e⁄cacy of ZK
191784 on inhibition of lymphocyte proliferation (MLR), surface
marker expression (HLA-DR, B7.1, ICAM-1) as well as cytokine
secretion (IL-12, TNF-a, and the regulatory cytokine IL-10) was
slightly reduced, pointing to some di¡erences in the biologic ac-
tivities of these two compounds. The aim of further studies was
to clarify whether the immunomodulatory pro¢le of ZK 191784
has consequences for activity in a T cell-dependent skin in£am-
mation model.
The DNFB-induced CHS model in mice is a delayed type hy-
persensitivity reaction mediated by lymphocytes primarily of the
Th1 subtype (Cher and Mosmann, 1987). After sensitization with
DNFB, subsequent challenge with the contact allergen results in
cutaneous in¢ltration of DNFB-primed T cells and their activa-
tion to produce in£ammatory cytokines, such as TNF-a and in-
terferon-g, representing important mediators in the CHS
reaction (Enk and Katz, 1992). Production of cytokines byT cells
is followed by recruitment and in¢ltration of other cells (mono-
cytes, macrophages, neutrophils, and lymphocytes) to the chal-
lenge site and the characteristic edema, peaking at 24^48 h after
challenge. Systemic treatment of mice with ZK 191784 or calci-
triol caused signi¢cant inhibition of the CHS in mice ears upon
topical challenge with DNFB (Fig 6). As immunosuppressive ef-
fects have been only induced when calcitriol derivatives were ad-
ministered around the ¢rst contact with the hapten, we
understand the APC (and the initial priming of T cells) as the
primary target. Our notion is supported by recent ¢ndings
showing that calcitriol strongly a¡ects activation of APC and
mainly indirectly T cell activation (Penna and Adorini, 2000).
The data on inhibition of MHC class II, costimulatory molecule
expression as well as IL-12 secretion by ZK 191784 and calcitriol
support the understanding of the action of calcitriol derivatives
in vivo.
Our data also point to di¡erences between activity of these
two compounds in the CHS model in mice. Only ZK 191784
showed dissociation of induction of immunosuppressive e¡ects
from hypercalcemia over a considerable dose range. In contrast
for calcitriol, doses e⁄cacious in inhibition of edema induced
also hypercalciuria and hypercalcemia. By reducing the dose of
calcitriol below 0.1 mg per kg per day in order to limit distur-
bance of calcium homeostasis the immunosuppressive activity
also diminished. Thus, ZK 191784 represents a new calcitriol ana-
log with clear dissociation of immunosuppressive and hypercalce-
mic activity and a reasonable therapeutic window. ZK 191784
inhibits the CHS only when applied around allergen sensitiza-
tion. Chronic immune disorders related to skin (e.g., psoriasis)
or other organ sites (e.g., rheumatoid arthritis) are characterized
by alternating remission and relapse periods with continuous
antigen presentation and T cell priming/activation. Therefore, we
suggest that compounds with this pro¢le might be of value in
chronic disease settings (e.g., prevention of relapse). Importantly,
for calcitriol, which behaves in a similar way to ZK 191784 in the
CHS, clinical e⁄cacy in psoriasis after systemic application has
been demonstrated (Perez et al, 1996).
What is the mechanism for dissociation of immunosuppressive
e¡ects from modulation of calcium homeostasis? One explana-
tion could be an in vivo metabolic stability of ZK 191784 that dif-
fers from the metabolic stability of the nondissociated calcitriol.
In vitro experiments with serum and organ homogenates (from
liver, kidney, or intestine from di¡erent species, including mice
and human) point to a weak metabolic stability of ZK 191784
compared with calcitriol (results not shown). It is possible that
for induction of immunosuppressive e¡ects a short presence of
ZK 191784 levels is su⁄cient, whereas for signi¢cant e¡ects on
the calcium homeostasis a longer presence of compound is
required. Another mechanism to be considered is the partial cal-
citriol agonism of ZK 191784. Although the relevance of the HL-
60 di¡erentiation by vitamin D compounds for the prediction of
in vivo activity is unclear, the antagonistic e¡ects of ZK 191784 on
HL-60 cells may re£ect a di¡erent tissue selectivity of the partial
agonist ZK 191784 compared with calcitriol. A unique tissue se-
lectivity has been recently described for tamoxifen, a partial ago-
nist for the estrogen receptor, representing another member of
the nuclear hormone receptor superfamily (Grese et al, 1997). In
these studies, tamoxifen exerts a breast-selective and bone-sparing
antagonistic action on estrogen. Recent ¢ndings suggest that the
structure of the VDR is altered in a vitamin D analog-speci¢c
way (Takeyama et al, 1999). It is likely that the distinct structure
of receptors ligated with agonist and antagonist and the interac-
tion with di¡erent coactivators or corepressors in each tissue may
be involved in the tissue-selective action of a partial agonist.
Although experimental proof is missing, we understand such
molecular mechanisms as possible explanations behind the disso-
ciation of immunosuppressive activity and hypercalcemia of ZK
191784.
Finally, the results in this study demonstrate that ZK 191784 is a
calcitriol derivative with unique properties. ZK 191784 is a ¢rst
representative of a novel class of immunosuppressive vitamin D
analogs with a considerable therapeutic window. Currently, in-
vestigations on further members of the novel vitamin D class
are ongoing to identify compounds with an even higher degree
of dissociation. Vitamin D compounds with a dissociated pro¢le
might represent promising therapeutic agents for systemic treat-
ment of chronic diseases withTcell dependency, such as psoriasis,
rheumatoid arthritis, in£ammatory bowel disease, or graft
rejection.
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